BTIG Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $40
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
BTIG analyst Kambiz Yazdi initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $40.
BTIG analyst Kambiz Yazdi initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $40.